EUVIMEDEUVIMED entdecken
Open Access

Serum Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn’s Disease

Romain Ferru-Clément, Gabrielle Boucher, Anik Forest, Bertrand Bouchard, Alain Bitton, Sylvie Lesage, Phil Schumm, Mark Lazarev, Steve Brant, Richard H Duerr, Dermot P B McGovern, Mark Silverberg und 6 weitere

Inflammatory Bowel Diseases · 05.07.2023 · 29 (7) · 1024-1037

DOI: 10.1093/ibd/izac281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 20.01.2023. Verfasst von Romain Ferru-Clément und 17 weiteren Autor:innen. Beteiligte Einrichtung: Research Center, Montreal Heart Institute, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Crohn Disease. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is an unmet medical need for biomarkers that capture host and environmental contributions in inflammatory bowel diseases (IBDs). This study aimed at testing the potential of circulating lipids as disease classifiers given their major roles in inflammation.

Methods

We applied a previously validated comprehensive high-resolution liquid chromatography-mass spectrometry–based untargeted lipidomic workflow covering 25 lipid subclasses to serum samples from 100 Crohn’s disease (CD) patients and 100 matched control subjects. Findings were replicated and expanded in another 200 CD patients and 200 control subjects. Key metabolites were tested for associations with disease behavior and location, and classification models were built and validated. Their association with disease activity was tested using an independent cohort of 42 CD patients.

Results

We identified >70 metabolites with strong association (P < 1 × 10-4, q < 5 × 10-4) to CD. Highly performing classification models (area under the curve > 0.84-0.97) could be built with as few as 5 to 9 different metabolites, representing 6 major correlated lipid clusters. These classifiers included a phosphatidylethanolamine ether (O-16:0/20:4), a sphingomyelin (d18:1/21:0) and a cholesterol ester (14:1), a very long-chain dicarboxylic acid [28:1(OH)] and sitosterol sulfate. These classifiers and correlated lipids indicate a dysregulated metabolism in host cells, notably in peroxisomes, as well as dysbiosis, oxidative stress, compromised inflammation resolution, or intestinal membrane integrity. A subset of these were associated with disease behavior or location.

Conclusions

Untargeted lipidomic analyses uncovered perturbations in the circulating human CD lipidome, likely resulting from multiple pathogenic mechanisms. Models using as few as 5 biomarkers had strong disease classifier characteristics, supporting their potential use in diagnosis or prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseHumansLipidomicsBiomarkersLipidsInflammation

Stichwörter der Autor:innen

Crohn’s diseasecomprehensive untargeted lipidomicslipid biomarkerssubtype stratification

Substanzen

BiomarkersLipids

Autor:innen und Institutionen

  • Research Center, Montreal Heart Institute, Montreal, QC, Canada.
  • Laboratoire Histocompatibilité et Immunogénétique, Établissement français du sang-Nouvelle-Aquitaine, site de Poitiers, Poitiers, France.
  • Division of Gastroenterology, McGill University Health Centre, Montreal, QC, Canada.
  • Maisonneuve-Rosemont Hospital Research Center, Montreal, QC, Canada.
  • Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.
  • Department of Public Health Sciences, University of Chicago, IL, USA.

ORCID-Profile: John D Rioux

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Ferru-Clément, R., Boucher, G., Forest, A., Bouchard, B., Bitton, A., Lesage, S., Schumm, P., Lazarev, M., Brant, S., Duerr, R. H., McGovern, D. P. B., Silverberg, M., Cho, J. H., NIDDK IBD Genetics Consortium, iGenoMed Consortium, Ananthakrishnan, A., Xavier, R. J., Rioux, J. D., & Des Rosiers, C. (2023). Serum Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn’s Disease. Inflammatory Bowel Diseases, 29(7), 1024-1037. https://doi.org/10.1093/ibd/izac281

Vancouver

Ferru-Clément R, Boucher G, Forest A, Bouchard B, Bitton A, Lesage S, et al. Serum Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn’s Disease. Inflammatory Bowel Diseases. 2023;29(7):1024-1037. doi:10.1093/ibd/izac281

BibTeX
@article{FerruClment2023,
  author = {Ferru-Clément, Romain and Boucher, Gabrielle and Forest, Anik and Bouchard, Bertrand and Bitton, Alain and Lesage, Sylvie and Schumm, Phil and Lazarev, Mark and Brant, Steve and Duerr, Richard H and McGovern, Dermot P B and Silverberg, Mark and Cho, Judy H and NIDDK IBD Genetics Consortium, iGenoMed Consortium, NIDDK IBD Genetics Consortium, iGenoMed Consortium and Ananthakrishnan, Ashwin and Xavier, Ramnik J and Rioux, John D and Des Rosiers, Christine},
  title = {Serum Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn’s Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  volume = {29},
  number = {7},
  pages = {1024--1037},
  doi = {10.1093/ibd/izac281}
}
Kostenlos starten →